$1.06
+0.00 (+0.00%)
Open$1.06
Previous Close$1.06
Day High$1.07
Day Low$1.05
52W High$3.15
52W Low$0.73
Volume—
Avg Volume72.9K
Market Cap44.37M
P/E Ratio—
EPS$-0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,322.6% upside
Current
$1.06
$1.06
Target
$15.08
$15.08
$11.92
$15.08 avg
$19.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.42M | 17.19M | 14.45M |
| Net Income | 959.9K | 1.03M | 875.1K |
| Profit Margin | 5.2% | 6.0% | 6.1% |
| EBITDA | 1.74M | 1.49M | 1.43M |
| Free Cash Flow | 993.5K | 1.08M | 606.8K |
| Rev Growth | +1.0% | +13.6% | +14.7% |
| Debt/Equity | 0.15 | 0.16 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |